打开APP

美国FDA批准NPS治疗短肠综合征的药物Gattex

  1. Gattex
  2. NPS公司
  3. 新药研发

来源:生物谷 2012-12-24 09:36

2012年12月22日讯 /生物谷BIOON/--美国FDA正式批注了总部位于新泽西的NPS公司的药物Gattex来治疗短肠综合征患者。该药物能帮助患者降低对静脉注射营养的依赖性。 但同时,FDA同时指出用这种药物的患者可能会有增加罹患癌症的风险和异常增生(息肉)在肠道,在肠阻塞,胆囊疾病、胆道疾病和胰腺疾病的潜在风险。 今年八月,Gattex获准在欧盟上市。

2012年12月22日讯 /生物谷BIOON/--美国FDA正式批注了总部位于新泽西的NPS公司的药物Gattex来治疗短肠综合征患者。该药物能帮助患者降低对静脉注射营养的依赖性。

但同时,FDA同时指出用这种药物的患者可能会有增加罹患癌症的风险和异常增生(息肉)在肠道,在肠阻塞,胆囊疾病、胆道疾病和胰腺疾病的潜在风险。

今年八月,Gattex获准在欧盟上市。(生物谷Bioon.com)

详细英文报道:

The FDA has stamped an approval on NPS Pharmaceuticals' ($NPSP) Gattex for treating patients with short bowel syndrome. The approval sets the stage for the U.S. launch of the company's lead drug and adds to U.S. regulators' impressive tally of more than 30 new drug nods in 2012.

The sanctioning of Gattex isn't a big surprise. FDA advisers unanimously endorsed the drug, which helps patients with the syndrome reduce their dependence on IV feeding, for approval in October. And most of them backed the REMS plan from the company to monitor cancer and other risks associated with the therapy.

The FDA noted today that patients on Gattex could face "increased risk of developing cancer and abnormal growths (polyps) in the intestine, obstructions in the intestine, gallbladder disease, biliary tract disease and pancreatic disease." The agency previously approved Zorbtive from Merck Serono and NutreStore from Emmaus for patients with short bowel syndrome, which is a relatively rare ailment that affects patients with Crohn's disease after they have a portion of their intestines removed.

"Today's approval expands the available treatment options for patients with this life-threatening condition," said Dr. Victoria Kusiak, of the FDA's Center for Drug Evaluation and Research, in a statement. "Because Gattex may cause other serious health conditions, it is critical that patients and health care professionals understand the drug's potential and known safety risks."

Bedminster, NJ-based NPS has been gearing up for the transition to the commercial realm this year, and CEO Francois Nader told FierceBiotech that 2012 would be transformational for his company back in January. He predicted well. In August, the European Commission green-lighted Gattex, a GLP-2 drug, in the EU where Takeda has marketing rights.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->